Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1

被引:66
作者
Guo, J
Chen, TY
Wang, BC
Zhang, MH
An, HZ
Guo, ZH
Yu, YZ
Qin, ZH
Cao, XT
机构
[1] Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China
[2] Jinan Gen Hosp PLA, Jinan, Peoples R China
基金
中国国家自然科学基金;
关键词
fractalkine; NK cells; chemotaxis; antitumor immunity; IL-12;
D O I
10.1016/S0165-2478(03)00101-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Fractalkine (FK, also called neurotactin or CX3CL1) is a CX3C chemokine that can chemoattract T lymphocytes, monocytes, dendritic cells (DC) and natural killer (NK) cells. One of our previous studies demonstrated that FK in soluble form can chemoattract T cells and DC and membrane-bound FK can adhere T cells and DC. Vaccination with 3LL lung carcinoma cells gene-modified with FK (3LL-FK) induces potent antitumor CTL response. The aim of the present study is to investigate whether NK cells participate in FK-induced antitumor immunity. We found that NK activity was increased in mice inoculated with 3LL-FK and in vivo depletion of NK cells resulted in the decreased tumor growth inhibition of 3LL-FK, indicating that NK cells play an important role in the antitumor immunity induced by FK. Further studies showed 3LL-FK could chemoattract, adhere NK cells and attract more NK cells to infiltrate into tumor tissue. Incubation of NK cells with 3LL-FK could increase the cytotoxicity of NK cells against YAC-1 cells and even against NK-resistant parental 3LL cells. IL-12 production increased more significantly in the 3LL-FK tumor nodules. Taken together with CTL response induced by 3LL-FK, our data demonstrate that FK, expressed by gene-modified tumor cells, can induce potent antitumor effect through different mechanisms, one of which involves chemoattraction of NK cells into tumor sites and activation of NK cells. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 31 条
[1]
A new class of membrane-bound chemokine with a CX(3)C motif [J].
Bazan, JF ;
Bacon, KB ;
Hardiman, G ;
Wang, W ;
Soo, K ;
Rossi, D ;
Greaves, DR ;
Zlotnik, A ;
Schall, TJ .
NATURE, 1997, 385 (6617) :640-644
[2]
Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
[3]
Enhanced antitumor effects of bone marrow transplantation in combination with fibroblast-mediated IL-2 and IL-3 gene therapy [J].
Cao, XT ;
Li, Q ;
Ju, DW ;
Wang, QX ;
Tao, Q ;
Wang, JL .
TRANSPLANTATION, 1999, 67 (09) :1242-1250
[4]
CEROSA F, 2002, J EXP MED, V195, P327
[5]
Natural killer cells, viruses and cancer [J].
Cerwenka, A ;
Lanier, LL .
NATURE REVIEWS IMMUNOLOGY, 2001, 1 (01) :41-49
[6]
In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II [J].
Chen, SH ;
Bacon, KB ;
Li, L ;
Garcia, GE ;
Xia, YY ;
Lo, D ;
Thompson, DA ;
Siani, MA ;
Yamamoto, T ;
Harrison, JK ;
Feng, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (01) :193-198
[7]
Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models [J].
Emtage, PCR ;
Wan, Y ;
Hitt, M ;
Graham, FL ;
Muller, WJ ;
Zlotnik, A ;
Gauldie, J .
HUMAN GENE THERAPY, 1999, 10 (05) :697-709
[8]
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow [J].
Fong, AM ;
Robinson, LA ;
Steeber, DA ;
Tedder, TF ;
Yoshie, O ;
Imai, T ;
Patel, DD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (08) :1413-1419
[9]
Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth [J].
Fushimi, T ;
Kojima, A ;
Moore, MAS ;
Crystal, RG .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (10) :1383-1393
[10]
Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells [J].
Guo, J ;
Zhang, MG ;
Wang, BC ;
Yuan, ZL ;
Guo, ZH ;
Chen, TY ;
Yu, YZ ;
Qin, ZH ;
Cao, XT .
INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (02) :212-220